Exploring the true immunotherapy candidates to acquire the promising immunological response in breast carcinomas

Abstract Background: Immune checkpoint blockade of immune therapy has been applied in multiple systemic malignancies, and have improved the overall survival to a greater extent, whether it will apply to breast cancer remains unknown. Methods: We endeavored to explore the possible factors that may influence the breast carcinoma associated immune therapy outcomes with using several public databases. Results: The possible treating target of TNF superfamily member 4 (TNFSF4), was selected from massive candidates for its abnormal expression profile, survival associated status, immune system reactions predication. For the first time, we revealed the oncogenic features of TNFSF4 in breast carcinoma, and TNFSF4 was further revealed to be closely related to anti-tumor immunity treatment, including multiple immune effector molecules and T-cell signatures, which was independent on endocrine status, and has not ever been referred to. Moreover, the immune treatment of TNFSF4 blockade also indicated the underling effects on stem cells’ expansion, which more strongly and specifically demonstrated the powerful effects of applying the TNFSF4 blockade based immune therapies in breast carcinomas. Conclusions: For the first time, we aim to dig out the embedding stars that may contribute to breast cancer therapies, and provide one potential but crucial potent for treating breast carcinoma indistinguishably, and long-term effective.